Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/20/2025

Erythrocytosis and Polycythemia

Definition and Normal Values

  • Normal hemoglobin values vary by age and gender, with adult males/post-menopausal females having 15.5 ± 2.0 g/dL, menstruating females having 14.0 ± 2.0 g/dL, and children having 11.5-14.5 g/dL 1

Diagnosis and Evaluation

  • Methemoglobinemia should be considered in the differential diagnosis when cyanosis is present despite normal oxygen saturation 2
  • Polycythemia is characterized by elevated hemoglobin and hematocrit levels, primarily caused by either true polycythemia or relative polycythemia, each with specific underlying etiologies that must be identified for proper management and prevention of adverse outcomes related to hyperviscosity 3
  • True polycythemia refers to an actual increase in red blood cell mass and can be divided into clonal myeloproliferative disorder characterized by JAK2 mutation (present in >97% of cases) and low serum erythropoietin levels (in most cases) 4, 3
  • Clonal myeloproliferative disorder is also characterized by characteristic bone marrow findings (hypercellularity, increased megakaryocytes) 3, 4
  • Causes of polycythemia include:
  • Initial assessment should include measuring hemoglobin, hematocrit, and red blood cell count, evaluating for clinical signs of dehydration, and assessing for hypoxemia with pulse oximetry 3
  • If elevated hemoglobin is confirmed, check erythropoietin levels, consider red cell mass measurement, evaluate for JAK2 mutations, screen for cardiopulmonary disease, and review medication history, particularly androgens/testosterone 3, 4, 7, 2

Management and Treatment

  • Management depends on the underlying cause, with phlebotomy to maintain hematocrit <45% and cytoreductive therapy in high-risk patients for polycythemia vera 3
  • Treatment options for specific causes of polycythemia:
  • Phlebotomy is indicated if hematocrit exceeds 54% or if the patient is symptomatic with a risk of hyperviscosity, with a target hematocrit of <45% to reduce the risk of thrombotic events, as recommended by the American College of Chest Physicians for patients with hyperviscosity syndrome 3

Complications and Risks

  • Cardiovascular complications can occur, particularly with hematocrit >54% 5
  • Increased risk of thrombotic events, hyperviscosity syndrome, headache, and dizziness are associated with elevated hemoglobin levels 6
  • Patients with pulmonary arterial hypertension (PAH) are sensitive to hemoglobin changes, and phlebotomy should be considered if hematocrit exceeds 65% and the patient is symptomatic, as recommended by the European Society of Cardiology 8